Biolex Therapeutics today announced successful results from the Phase I clinical trial of Locteron. Locteron uses BLX-883, a recombinant alfa interferon.
The trial demonstrated the safety and tolerability of Locteron given as a single dose to healthy volunteers, and the pharmacokinetic and pharmacodynamic results support dosing every two weeks, a substantial improvement over currently marketed pegylated interferons that require dosing every week. Based on these results, the company expects Locteron to enter Phase II clinical testing in the second half of 2006.
